Open access

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
Weinan Guo, Zhenjie Wu, Jianru Chen, Sen Guo, Weiming You, Sijia Wang, Jinyuan Ma, Huina Wang, Xiangxu Wang, Hao Wang, Jingjing Ma, Yuqi Yang, Yangzi Tian, Qiong Shi, Tianwen Gao, Xiuli Yi, Chunying Li

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004381; DOI: 10.1136/jitc-2021-004381
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes, Jonas Mattsson, Andreas Lundqvist, Elias S J Arnér, Rolf Kiessling, Stina Linnea Wickström

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004458; DOI: 10.1136/jitc-2021-004458
Resistance to systemic immune checkpoint inhibition in the peritoneal niche
Daryl Kai Ann Chia, Yong Xiang Gwee, Raghav Sundar

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004749; DOI: 10.1136/jitc-2022-004749
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
Pei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, Chieh Ju Lee, Chen-Ta Chi, I-Cheng Lee, Kuo Yu-Lun, Shih-Hsuan Chou, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004779; DOI: 10.1136/jitc-2022-004779
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
Beatrice Thier, Fang Zhao, Simone Stupia, Alicia Brüggemann, Johannes Koch, Nina Schulze, Susanne Horn, Christoph Coch, Gunther Hartmann, Antje Sucker, Dirk Schadendorf, Annette Paschen

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003863; DOI: 10.1136/jitc-2021-003863
Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
Danielle E Dettling, Eilene Kwok, Lucy Quach, Aakash Datt, Jeremiah D Degenhardt, Anand Panchal, Pui Seto, Jessica L Krakow, Russell Wall, Brian J Hillier, Ying Zhu, Maia Vinogradova, Robert B DuBridge, Chad May

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004336; DOI: 10.1136/jitc-2021-004336
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004984; DOI: 10.1136/jitc-2022-004984
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C Williams

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003752; DOI: 10.1136/jitc-2021-003752
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Christine M Minnar, Paul L Chariou, Lucas A Horn, Kristin C Hicks, Claudia Palena, Jeffrey Schlom, Sofia R Gameiro

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004561; DOI: 10.1136/jitc-2022-004561
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal, James Garrett, Alexander Savchenko, Güllü Görgün, Keith T Flaherty, Antoni Ribas, Reinhard Dummer, Dirk Schadendorf, Georgina V Long, Paul D Nathan, Paolo A Ascierto

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004226; DOI: 10.1136/jitc-2021-004226

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages